Author Correction: HER Kinase Inhibition in Patients With HER2- And HER3-mutant Cancers

Nature - United Kingdom
doi 10.1038/s41586-019-0974-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Cancer Discovery
Oncology
2019English

Outcomes of Chemotherapies and HER2 Directed Therapies in Advanced HER2-mutant Lung Cancers

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2016English

HER3 Over-Expression and Overall Survival in Gastrointestinal Cancers

Oncotarget
Oncology
2015English

Novel Agents That Downregulate EGFR, HER2, and HER3 in Parallel

Oncotarget
Oncology
2015English

Author Correction: Genomic Characterization of Metastatic Breast Cancers

Nature
Multidisciplinary
2019English

Positive Prognostic Value of HER2-HER3 Co-Expression and P-mTOR in Gastric Cancer Patients

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

Inhibition of EGFR, HER2, and HER3 Signalling in Patients With Colorectal Cancer Wild-Type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): A Phase 2–3 Randomised Trial

Lancet Gastroenterology and Hepatology, The
HepatologyGastroenterology
2018English

ZW25 Active in HER2-positive Cancers

Cancer Discovery
Oncology
2018English

MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy